Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
EMBC vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
EMBC vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $214M | $1712.35T |
| Revenue (TTM) | $1.04B | $0.00 |
| Net Income (TTM) | $112M | $-168M |
| Gross Margin | 61.4% | — |
| Operating Margin | 27.7% | — |
| Forward P/E | 1.3x | — |
| Total Debt | $1.43B | $22M |
| Cash & Equiv. | $226M | $194M |
EMBC vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| Embecta Corp. (EMBC) | 100 | 10.8 | -89.2% |
| DBV Technologies S.… (DBVT) | 100 | 125.7 | +25.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EMBC vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EMBC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.31, yield 16.5%
- Rev growth -3.8%, EPS growth 20.9%, 3Y rev CAGR -1.5%
- -3.8% revenue growth vs DBVT's -100.0%
DBVT is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- -87.0% 10Y total return vs EMBC's -87.6%
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -3.8% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 10.7% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 1.26 vs EMBC's 1.31 | |
| Dividends | 16.5% yield; 1-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs EMBC's -66.3% | |
| Efficiency (ROA) | 10.3% ROA vs DBVT's -89.0% |
EMBC vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
EMBC vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
EMBC and DBVT operate at a comparable scale, with $1.0B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.0B | $0 |
| EBITDAEarnings before interest/tax | $316M | -$112M |
| Net IncomeAfter-tax profit | $112M | -$168M |
| Free Cash FlowCash after capex | $174M | -$151M |
| Gross MarginGross profit ÷ Revenue | +61.4% | — |
| Operating MarginEBIT ÷ Revenue | +27.7% | — |
| Net MarginNet income ÷ Revenue | +10.7% | — |
| FCF MarginFCF ÷ Revenue | +16.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -14.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -2.9% | +91.5% |
Valuation Metrics
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $214M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | 2.22x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.28x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 3.73x | — |
| Price / SalesMarket cap ÷ Revenue | 0.20x | — |
| Price / BookPrice ÷ Book value/share | — | 0.66x |
| Price / FCFMarket cap ÷ FCF | 1.17x | — |
Profitability & Efficiency
EMBC leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), EMBC scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -130.2% |
| ROA (TTM)Return on assets | +10.3% | -89.0% |
| ROICReturn on invested capital | +42.7% | — |
| ROCEReturn on capital employed | +37.8% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $1.2B | -$172M |
| Cash & Equiv.Liquid assets | $226M | $194M |
| Total DebtShort + long-term debt | $1.4B | $22M |
| Interest CoverageEBIT ÷ Interest expense | 39.48x | -189.82x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $1,245 for EMBC. Over the past 12 months, DBVT leads with a +110.4% total return vs EMBC's -66.3%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs EMBC's -43.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -67.8% | +4.9% |
| 1-Year ReturnPast 12 months | -66.3% | +110.4% |
| 3-Year ReturnCumulative with dividends | -81.6% | +19.7% |
| 5-Year ReturnCumulative with dividends | -87.6% | -69.1% |
| 10-Year ReturnCumulative with dividends | -87.6% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -43.1% | +6.2% |
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than EMBC's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs EMBC's 23.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 1.26x |
| 52-Week HighHighest price in past year | $15.55 | $26.18 |
| 52-Week LowLowest price in past year | $3.45 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +23.2% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 13.7 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 252K |
Analyst Outlook
EMBC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates EMBC as "Sell" and DBVT as "Buy". Consensus price targets imply 233.3% upside for EMBC (target: $12) vs 131.8% for DBVT (target: $46). EMBC is the only dividend payer here at 16.50% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Sell | Buy |
| Price TargetConsensus 12-month target | $12.00 | $46.33 |
| # AnalystsCovering analysts | 4 | 15 |
| Dividend YieldAnnual dividend ÷ price | +16.5% | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | $0.59 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.7% | 0.0% |
DBVT leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). EMBC leads in 2 (Profitability & Efficiency, Analyst Outlook).
EMBC vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is EMBC or DBVT a better buy right now?
Embecta Corp.
(EMBC) offers the better valuation at 2. 2x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EMBC or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -87. 6% for Embecta Corp. (EMBC). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus EMBC's -87. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EMBC or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Embecta Corp. 's 1. 31β — meaning EMBC is approximately 4% more volatile than DBVT relative to the S&P 500.
04Which is growing faster — EMBC or DBVT?
On earnings-per-share growth, the picture is similar: Embecta Corp.
grew EPS 20. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EMBC or DBVT?
Embecta Corp.
(EMBC) is the more profitable company, earning 8. 8% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMBC leads at 30. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — EMBC leads at 62. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is EMBC or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for EMBC: 233.
3% to $12. 00.
07Which pays a better dividend — EMBC or DBVT?
In this comparison, EMBC (16.
5% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.
08Is EMBC or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Embecta Corp.
(EMBC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (16. 5% yield). Both have compounded well over 10 years (EMBC: -87. 6%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between EMBC and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EMBC is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock. EMBC pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.